Altered IgG4 renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity

Nephrology Dialysis Transplantation

Volumn 15, Issue 4, 2000, Pages 498-501

  Monteleone, Giovanni ^a   Cristina, Giuseppe ^b   Parrello, Tiziana ^a   Morano, Susanna ^b   Biancone, Livia ^a   Pietravalle, Patrizia ^b   Sagratella, Elisabetta ^b   Doldo, Patrizia ^a   Luzza, Francesco ^a   Di Mario, Umberto ^a   Pallone, Francesco ^a,c  

^a Universitá di Roma   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Policlinico Universitario   (Italy)

Author keywords

Antineutrophil antibodies; Crohn's disease; Proteinuria; Renal permselectivity; Ulcerative colitis

Indexed keywords

ALBUMIN; ANION; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON CROHN DISEASE; CONTROLLED STUDY; ELECTRICITY; ENTERITIS; GLOMERULUS FILTRATION; HUMAN; KIDNEY CLEARANCE; PRIORITY JOURNAL; PROTEINURIA; ULCERATIVE COLITIS;

EID: 0034102201     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.4.498     Document Type: Article

References (20)

1. Mahmud N, Stinson J, O'Connell MA et al. Microalbuminuria in inflammatory bowel disease. Gut 1994; 35: 1599-1604
2. Brenner BM, Hosteller TH, Humes HD. Molecular basis of proteinuria of glomerular origin. N Engl J Med 1978; 298; 826-833
3. Cotran RS, Rennke HG. Anionic sites and the mechanisms of proteinuria. N Engl J Med 1983; 309: 1050-1052
4. Rosenzweig LJ, Kanwar YS. Removal of sulfated (heparan sulphate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125-I-bovine serum albumin. Lab Invest 1982; 47: 177-184
5. Di Mario U, Morano S, Cancelli A et al. New parameters to monitor the progression of diabetic nephropathy. Am J Kidney Dis 1989; 13: 45-48
6. Sumpio BR, Maack T. Kinetics, competition, and selectivity of tubular absorption of proteins. Am J Physiol 1982; 243: 379-392
7. Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993; 341: 711-714
8. Truelove SC, Witts LJ. Cortisone in ulcerative colilis: final report of a therapeutic trial. Br Med J 1955; 2: 1041-1048
9. Best WR, Becktel JM, Singleton JW, Kern K. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-444
10. Di Mario U, Pietravalle P, Napoli A et al. A sensitive routine assay for urinary albumin based on the competitive binding to anti-albumin antibodies in solid phase. Horm Metab Res 1986; 18: 689-692
11. Di Mario U, Morano S, Mancuso M et al. Urinary immunoglobulin G: a routine and highly sensitive technique based on competitive binding. J Clin Lab Immunol 1986; 20: 155-158
12. Morano S, Cancelli A, Mancuso M et al. Sensitive immunoenzymatic assay for urinary immunoglobulins of different pH: its significance in diabetic patients. Diabetes Res 1987; 6: 181-185
13. Monteleone G, Marasco R, Parrello T et al. Low prevalence of p-ANCA in unaffected relatives of patients wilh ulcerative colitis from a Mediterranean area. Inflamm Bowel Dix 1996; 2: 11-15
14. Mahmud N, O'Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D. Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7; 215-219
15. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-572
16. Calder IC, Funder CC, Green CR, Ham KN, Tange JD. Nephrotoxicity lesion from 5-aminosalicylic acid. Br Med J 1972; 1: 152-154
17. Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493-1496
18. Colombel J-F, Brabant G, Gubler M-C et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994; 344: 620-621
19. Schreiber S, Hamling J, Zehnter H et al. Renal tubular dysfunction in patients wilh inflammatory bowel disease treated with aminosalicylate. Gut 1997; 40: 761-766
20. Pietravalle P, Morano S, Cristina G et al. Charge selectivity of proteinuria in type I diabetes explored by Ig subclass clearance. Diabetes 1991; 40: 1685-1690